Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 7, 2014, Pages 1056-1066

  Memon, Khairuddin ^a   Kulik, Laura M ^a   Lewandowski, Robert J ^a   Wang, Edward ^a   Wang, Jonathan ^a   Ryu, Robert K ^a   Hickey, Ryan ^a   Vouche, Michael ^a   Baker, Talia ^a   Ganger, Daniel ^a   Gates, Vanessa L ^a   Habib, Ali ^a   Mulcahy, Mary F ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; CARCINOMA, HEPATOCELLULAR; CHI SQUARE DISTRIBUTION; DECISION SUPPORT SYSTEM; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84903269161     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2014.01.010     Document Type: Article

References (39)

1. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
2. J. Bruix, M. Sherman, and J.M. Llovet et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
3. V. Mazzaferro, C. Sposito, and S. Bhoori et al. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: a phase II study Hepatology 57 2013 1826 1837
4. R. Salem, V. Mazzaferro, and B. Sangro Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges and clinical perspectives Hepatology 58 2013 2188 2197
5. R. Salem, R.J. Lewandowski, and L. Kulik et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2011 497 507 e492
6. B. Sangro, L. Carpanese, and R. Cianni et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation Hepatology 54 2011 868 878
7. K. Memon, L. Kulik, and R.J. Lewandowski et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression J Hepatol 58 2013 73 80
8. C.S. Georgiades, E. Liapi, and C. Frangakis et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization J Vasc Interv Radiol 17 2006 1619 1624
9. D.B. Brown, C.E. Fundakowski, and M. Lisker-Melman et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma J Vasc Interv Radiol 15 2004 1209 1218
10. Chen C-H, Hu F-C, Huang G-T, et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - analysis of 2010 Taiwanese patients. Eur J Cancer 2009; 45:1630-1639.
11. J.-C. Trinchet, and M. Beaugrand Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail J Hepatol 53 2010 23 24
12. P. Hilgard, M. Hamami, and A.E. Fouly et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
13. R. Salem, R.J. Lewandowski, and M.F. Mulcahy et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
14. J.A. Marrero, R.J. Fontana, and A. Barrat et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort Hepatology 41 2005 707 716
15. F.D. Huitzil-Melendez, M. Capanu, and E.M. O'Reilly et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28 2010 2889 2895
16. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
17. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix et al. Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
18. R. Salem, and K.G. Thurston Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
19. R. Salem, R.J. Lewandowski, and V.L. Gates et al. Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 2011 265 278
20. C.G. Child, and J.G. Turcotte Surgery and portal hypertension Major Probl Clin Surg 1 1964 1 85
21. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
22. K. Okuda, T. Ohtsuki, and H. Obata et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients Cancer 56 1985 918 928
23. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators Hepatology 28 1998 751 755
24. S. Chevret, J.C. Trinchet, D. Mathieu, A.A. Rached, M. Beaugrand, and C. Chastang A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire J Hepatol 31 1999 133 141
25. T.W. Leung, A.M. Tang, and B. Zee et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients Cancer 94 2002 1760 1769
26. M. Kudo, H. Chung, and Y. Osaki Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) J Gastroenterol 38 2003 207 215
27. D.W. Hosmer, T. Hosmer, S. Le Cessie, and S. Lemeshow A comparison of goodness-of-fit tests for the logistic regression model Stat Med 16 1997 965 980
28. A.R. Feinstein Clinical biostatistics. XVI. The process of prognostic stratification. 2 Clin Pharmacol Ther 13 1972 609 624
29. M.R. Forster Key concepts in model selection: performance and generalizability J Math Psychol 44 2000 205 231
30. M.J. Pencina, and R.B. D'Agostino Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation Stat Med 23 2004 2109 2123
31. T.J. Cleophas, and A.H. Zwinderman Clinical trials are often false positive: a review of simple methods to control this problem Curr Clin Pharmacol 1 2006 1 4
32. G.K. Abou-Alfa Hepatocellular carcinoma: molecular biology and therapy Semin Oncol 33 6 Suppl 11 2006 S79 S83
33. U. Cillo, A. Vitale, and F. Grigoletto et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system J Hepatol 44 2006 723 731
34. D. D'Avola, M. Iñarrairaegui, and F. Pardo et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages Ann Surg Oncol 18 2011 1964 1971
35. M. Burrel, M. Reig, and A. Forner et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
36. S. Ueno, G. Tanabe, and K. Sako et al. Discrimination value of the new Western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program Hepatology 34 2001 529 534
37. I. Levy, and M. Sherman Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto Gut 50 2002 881 885
38. F. Farinati, M. Rinaldi, S. Gianni, and R. Naccarato How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system Cancer 89 2000 2266 2273
39. J.M. Henderson, M. Sherman, A. Tavill, M. Abecassis, G. Chejfec, and T. Gramlich AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement HPB (Oxford) 5 2003 243 250